Enlivex (ENLV) Notes Payables (2016 - 2020)

Enlivex (ENLV) posted quarterly Notes Payables of $380000.0 for Q1 2020, up 3.54% quarter-over-quarter from $367000.0 in Q4 2019.

Enlivex (ENLV) Notes Payables (2016 - 2020) Analysis & Trends

Enlivex's Notes Payables history runs 5 years deep, the most recent figure standing at $380000.0 for Q1 2020.

In Q1 2020, Notes Payables changed N/A year-over-year to $380000.0; the TTM figure through Mar 2020 stood at $380000.0 (changed N/A YoY), while the FY2019 annual figure was $367000.0, up 2723.08% from the prior year.
Notes Payables for Q1 2020 stood at $380000.0, up from $367000.0 in the prior quarter.
The five-year high for Notes Payables was $380000.0 in Q1 2020, with the low at $13000.0 in Q4 2018.
The 5-year median for Notes Payables is $28000.0 (2016), against an average of $162600.0.
The sharpest annual moves came in 2018 and 2019: Notes Payables tumbled 48.0% in 2018, then jumped 2723.08% in 2019.
Enlivex's Notes Payables stood at $28000.0 in 2016, then declined by 10.71% to $25000.0 in 2017, then sank by 48.0% to $13000.0 in 2018, then surged by 2723.08% to $367000.0 in 2019, then increased by 3.54% to $380000.0 in 2020.
Business Quant data shows ENLV's Notes Payables at $380000.0 in Q1 2020, $367000.0 in Q4 2019, and $13000.0 in Q4 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	Enlivex	4.58 Mn	-1.17 Mn	-

Download Data